SILVER SPRING, Md. and SAN RAMON, Calif., April 30, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) and SteadyMed Ltd. (NASDAQ: STDY)
announced today the signing of a definitive merger agreement under which United Therapeutics will acquire SteadyMed for
$4.46 per share in cash at closing and an additional $2.63 per share
in cash upon the achievement of a milestone related to the commercialization of Trevyent®. The transaction, including the
$75 million in contingent consideration, is valued at $216
million.
SteadyMed is a specialty pharmaceutical company focused on the development and commercialization of drug product candidates to
treat orphan and high-value diseases with unmet parenteral delivery needs. SteadyMed's product portfolio includes Trevyent, a
development-stage drug-device combination product that combines SteadyMed's two day, single use, disposable PatchPump® technology
with treprostinil, a vasodilatory prostacyclin analogue, for the subcutaneous treatment of pulmonary arterial hypertension (PAH).
United Therapeutics is a leading biotechnology company focused on the development and commercialization of therapies for the
treatment of PAH and other orphan diseases.
"We are optimistic about acquiring SteadyMed and adding Trevyent to our pipeline of products to treat PAH," said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics. "We are especially
impressed with SteadyMed's management team and global supply chain. Trevyent fits in well with our mission, and we look forward
to bringing the product to the maximum number of patients as soon as possible."
"United Therapeutics has always been at the forefront of developing therapies to treat PAH, and we are delighted at the
prospect of our companies coming together, as one, to continue that mission," said Jonathan M.N.
Rigby, President and Chief Executive Officer of SteadyMed. "We believe that this proposed acquisition will help us realize
our commitment to bring Trevyent to market to improve the lives of patients with PAH."
The Board of Directors of SteadyMed has unanimously approved the merger agreement and unanimously recommends that SteadyMed
shareholders adopt the merger agreement. SteadyMed shareholders owning approximately 43.3 percent of the ordinary shares of
SteadyMed have entered into an agreement to vote their shares in favor of the transaction.
The transaction is subject to customary closing conditions, including approval by SteadyMed's shareholders and the expiration
or termination of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, and is expected to be
completed in the third quarter of this year.
United Therapeutics received legal advice from Gibson, Dunn & Crutcher and Herzog, Fox & Neeman; SteadyMed received
legal advice from Cooley LLP and Yigal Arnon & Co.; and Wedbush PacGrow acted as an advisor to
the SteadyMed Board of Directors.
About United Therapeutics
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative
products to address the unmet medical needs of patients with chronic and life-threatening conditions.
About SteadyMed Ltd .
SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high
value diseases with unmet parenteral delivery needs. The company's lead drug product candidate is Trevyent, a development-stage
drug-device combination product that combines SteadyMed's PatchPump technology with treprostinil, a vasodilatory prostacyclin
analogue to treat PAH. SteadyMed has signed an exclusive license and supply agreement with Cardiome Pharma Corp. for the
commercialization of Trevyent in Europe and the Middle East. In
March 2018, Cardiome sublicensed its rights to sell Trevyent in Canada to Cipher Pharmaceuticals. SteadyMed has offices in San Ramon,
California and Rehovot, Israel. For additional information about SteadyMed please visit
www.steadymed.com.
Additional Information and Where to Find It
In connection with the proposed merger, SteadyMed intends to file relevant materials with the Securities and Exchange
Commission (the "SEC"), including a proxy statement on Schedule 14A. Promptly after filing its definitive proxy statement with
the SEC, SteadyMed will mail the definitive proxy statement and a proxy card to each shareholder entitled to vote at the special
meeting relating to the transaction. STEADYMED INVESTORS AND SHAREHOLDERS ARE URGED TO READ THESE MATERIALS (INCLUDING ANY
AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE TRANSACTION THAT STEADYMED WILL FILE
WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT STEADYMED AND THE TRANSACTION. The
definitive proxy statement, the preliminary proxy statement and other relevant materials in connection with the transaction (when
they become available), and any other documents filed by SteadyMed with the SEC, may be obtained free of charge at the SEC's
website (http://www.sec.gov) or at SteadyMed's website (http://ir.steadymed.com) or by writing to Marylyn
Rigby, Investor Relations, SteadyMed Ltd., c/o SteadyMed Therapeutics, Inc., 2603 Camino Ramon, Suite 350, San Ramon, California, 94583.
SteadyMed and its directors and executive officers are participants in the solicitation of proxies from SteadyMed's
shareholders with respect to the transaction. Information about SteadyMed's directors and executive officers and their ownership
of SteadyMed ordinary shares is set forth in SteadyMed's Annual Report on Form 10-K filed with the SEC on March 30, 2018. To the extent that holdings of SteadyMed's securities have changed since the amounts printed in
SteadyMed's proxy statement, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed
with the SEC. Information regarding the identity of the participants, and their direct or indirect interests in the transaction,
by security holdings or otherwise, will be set forth in the proxy statement and other materials to be filed with SEC in
connection with the transaction.
Forward-looking Statements
Statements included in this press release that are not historical in nature are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements related to the timing
of the consummation of the business combination transaction between United Therapeutics and SteadyMed. Forward-looking statements
are based on United Therapeutics or SteadyMed management's beliefs, as well as assumptions made by, and information currently
available to, them. Because such statements are based on expectations as to future events and results and are not statements of
fact, actual events and results may differ materially from those projected depending on a number of factors affecting the
transaction and SteadyMed's business. United Therapeutics and SteadyMed are providing this information as of April 30, 2018 and undertake no obligation to update or revise the information contained in this press release
whether as a result of new information, future events or any other reason. The risks and uncertainties which forward-looking
statements are subject to include, but are not limited to: the risk that the transaction may not be completed in a timely manner
or at all, which may adversely affect SteadyMed's business and the price of the ordinary shares of SteadyMed; the failure to
satisfy the conditions to the consummation of the transaction, including the adoption of the merger agreement by the shareholders
of SteadyMed and the expiration or termination of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements
Act; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement;
the effect of the announcement or pendency of the transaction on SteadyMed's business relationships, operating results, and
business generally; risks that the proposed transaction disrupts current plans and operations of SteadyMed or United Therapeutics
and potential difficulties in SteadyMed employee retention as a result of the transaction; risks related to diverting
management's attention from SteadyMed's ongoing business operations; the outcome of any legal proceedings that may be instituted
against SteadyMed related to the merger agreement or the transaction; the ability of United Therapeutics to successfully
integrate SteadyMed's operations, product lines, and technology; future clinical results; the timing or outcome
of FDA approvals or actions, if any; and other risks and uncertainties, such as those described in periodic and other
reports filed by United Therapeutics and SteadyMed with the Securities and Exchange Commission, including their respective most
recent Annual Reports on Form 10-K and Current Reports on Form 8-K.
TREVYENT and PATCHPUMP are registered trademarks of SteadyMed Ltd.
View original content:http://www.prnewswire.com/news-releases/united-therapeutics-to-acquire-steadymed-ltd-300638666.html
SOURCE United Therapeutics Corporation; SteadyMed